Abstract 119P
Background
To conduct a comparative analysis of the effectiveness of hypofractional and classical radiotherapy regimens in neoadjuvant chemoradiotherapy for locally advanced rectal cancer (LARC).
Methods
This study based on a retrospective analysis of a database in patients with LARC who underwent a course of neoadjuvant chemoradiotherapy followed by surgery. The patients were divided into two groups: the first (main) group, 104 patients who underwent a course of hypofractionated chemotherapy (4 Gy x 40 Gy 3 fractions per week) in combination with capecitabine 1650 mg/m2 in two doses. The second group (control group) included 120 patients who underwent a course of CRT in the classical fractionation regimen (2 Gy x 50-58 Gy 5 fractions per week) in combination with capecitabine 1650 mg/m2 in two doses. The main evaluated indicators are the frequency of pCR and cCR. Additional assessed indicators are the severity of early radiation toxicity, the frequency of local relapses, overall and disease-free survival.
Results
The study included 224 patients. The average duration of the CRT course in the study group was 22.56 (95% CI from 21.94 to 23.18) days, in the control group - 38.84 (95% CI from 38.12 to 39.54), p=0.0001. Radiation toxicity grade III and IV was registered in 5.75% of patients in the study group and in 6.41% of patients in the control group. pCR in the study groups was achieved in 19.23% and 15.83% of cases, respectively, p=0.504. The cCR in the studied groups was achieved in 25% and 18.3% of cases, respectively, p=0.226. The median time without progression was 37.6 months. In the main and control groups, local control rates were 91.34% and 88.3% respectively, p=0.954, HR=1.05 (95% CI 0.21 to 5.22). Five-year disease-free survival in the main group was 71.1% and in the control group 60.8%, respectively, p=0.353, HR=0.79 (95% CI 0.42 to 1.35). Five-year overall survival in the main and control groups were 81.7% and 79.2%, respectively, p=0.743, HR=0.87 (95% CI 0.39 to 1.92).
Conclusions
Thus, the hypofractionation regimen showed high antitumor efficacy and can be considered as an alternative and not inferior to the classical regimen in neoadjuvant CRT in patients with LARC.
Clinical trial identification
N/A
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
111P - Comparison of the efficacy and safety of fruquintinib and fruquintinib combined with immune checkpoint inhibitors in the treatment of metastatic microsatellite stable colorectal cancer: A real-world study
Presenter: Zhiqiang Wang
Session: Poster Display
Resources:
Abstract
112P - Optimal classification and treatment strategy based on technical and oncological futures in recurrence of colorectal liver metastases
Presenter: Kosuke Kobayashi
Session: Poster Display
Resources:
Abstract
113P - Phase I/II study of capecitabine(C)/oxaliplatin(O)/irinotecan(I) combined with bevacizumab(B) in the first-line treatment of metastatic colorectal cancer (mCRC)
Presenter: Kai Ou
Session: Poster Display
Resources:
Abstract
114P - The prognostic role of LAG-3 expression in metastatic colorectal cancer
Presenter: Yi-Hsuan Huang
Session: Poster Display
Resources:
Abstract
115P - Sidedness and survival of chemo-refractory metastatic colorectal cancer treated with lonsurf or regorafenib: A nationwide population-based study in Taiwan
Presenter: Meng-Che Hsieh
Session: Poster Display
Resources:
Abstract
116P - Burden and trends of colorectal cancer in high income Asia Pacific countries from 1990-2019 and its projections of deaths to 2040: A comparative analysis
Presenter: Monika Chhayani
Session: Poster Display
Resources:
Abstract
117P - Australasian real-world treatment selection and clinical outcomes for patients with left side (LS), RAS wildtype (RASwt) metastatic colorectal cancer (mCRC)
Presenter: Vanessa Wong
Session: Poster Display
Resources:
Abstract
120P - Improved clinical outcomes with cetuximab maintenance therapy in left-sided RAS/BRAF wild-type metastatic colorectal cancer: A real-world study of Hunan cancer hospital
Presenter: Xiaolin Yang
Session: Poster Display
Resources:
Abstract
121P - Single-cell sequencing reveals the role of Treg cells with high expression of BIRC3 in regulating the progression of colorectal cancer
Presenter: Yuqiu Xu
Session: Poster Display
Resources:
Abstract
122P - Distinct transcriptomic immune profiling and clinicopathological features of cribriform morphology in colorectal adenocarcinomas
Presenter: Abdelhakim Khellaf
Session: Poster Display
Resources:
Abstract